CMS (00867) announced that its Class 1 new drug anti-IL-4Rα MG-K10 humanized monoclonal antibody injection (MG-K10), for which the group holds co-development rights (excluding atopic dermatitis) and exclusive commercialization rights, received a drug clinical trial approval notice from China's National Medical Products Administration (NMPA) on September 29, 2025. The NMPA has approved the initiation of clinical trials for MG-K10 in the treatment of chronic obstructive pulmonary disease (COPD).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.